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ABSTRACT
Background
More than 35 million people in developing countries are living with HIV infection. An
enormous global effort is now underway to bring antiretroviral treatment to at least 3 million of
those infected. While drug prices have dropped considerably, the cost and technical complexity
of laboratory tests essential for the management of HIV disease, such as CD4 cell counts,
remain prohibitive. New, simple, and affordable methods for measuring CD4 cells that can be
implemented in resource-scarce settings are urgently needed.
Methods and Findings
Here we describe the development of a prototype for a simple, rapid, and affordable method
for counting CD4 lymphocytes. Microliter volumes of blood without further sample preparation
are stained with fluorescent antibodies, captured on a membrane within a miniaturized flow
cell and imaged through microscope optics with the type of charge-coupled device developed
for digital camera technology. An associated computer algorithm converts the raw digital
image into absolute CD4 counts and CD4 percentages in real time. The accuracy of this
prototype system was validated through testing in the United States and Botswana, and
showed close agreement with standard flow cytometry (r¼0.95) over a range of absolute CD4
counts, and the ability to discriminate clinically relevant CD4 count thresholds with high
sensitivity and specificity.
Conclusion
Advances in the adaptation of new technologies to biomedical detection systems, such as
the one described here, promise to make complex diagnostics for HIV and other infectious
diseases a practical global reality.
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More than 35 million HIV-infected people live in develop-
ing countries with signiﬁcant resource limitations. Although
6 million people living in developing countries are in urgent
need of antiretroviral therapy, only 700,000 currently receive
effective treatment [1]. Global treatment efforts, including
the World Health Organization’s ‘‘3b y5 ’’ Initiative, aim to
extend therapy to several million people over the next few
years [2]. While the cost of antiretroviral medications has
dropped considerably, other obstacles, including the cost,
technical, and operational requirements of CD4 counts, viral
loads, and other sophisticated diagnostic tests used to initiate
and monitor HIV treatment, remain to be addressed.
In particular, measurements of CD4
þ T lymphocytes are
essential for staging HIV-infected patients, determining their
need for antiretroviral medications, and monitoring the
course of their infection [3]. The CD4 count—expressed in
adults as the absolute number of CD4 cells per microliter of
blood, and in children as a percentage of total lymphocytes or
total T lymphocytes—has enormous prognostic and thera-
peutic implications, and forms the basis for most HIV
treatment decisions [4–6]. In developed countries, CD4
counts are typically performed every three to six months
for each patient using the method of ﬂow cytometry. Flow
cytometers use lasers to excite ﬂuorescent antibody probes
speciﬁc for CD4 and other cell surface markers, to distinguish
one type of lymphocyte from another. Several factors—
including the cost of a ﬂow cytometer (which ranges from
$30,000 to $150,000), technical and operational complexity,
the need for reliable electricity, and the high cost of
reagents—have made these instruments impractical and/or
difﬁcult to sustain in resource-scarce settings. The urgent
need for affordable and technically simple CD4 diagnostics is
widely recognized [7–11].
Several efforts have been made to develop alternative,
affordable CD4 counting methods for resource-poor settings.
Single-purpose ﬂow cytometers have been designed solely for
counting CD4 cells, such as the Becton Dickinson FACS-
Count, the Partec CyFlow, and desktop instruments from
Guava and PointCare Technologies. Although these newer
versions make ﬂow cytometry more affordable in some
settings, reagent costs remain high, and the instruments
remain expensive and in most cases, technically complex [7–
13]. Low-cost microbead separation of CD4 cells from other
blood cells, followed by standard manual cell counting
techniques using a light microscope, offers signiﬁcantly lower
reagent costs than ﬂow cytometry. These methods, however,
are low throughput and extremely labor intensive, and
appear to be less accurate than traditional ﬂow cytometry;
thus, they have not been widely adopted [13–18].
Less expensive CD4 counting methods that capitalize on
low-cost microfabrication, efﬁcient light sources, and afford-
able microelectronics and digital imaging hardware have
been conceptualized, but never realized [19,20]. One of us
(JTM) has previously reported the development of a novel
microchip-based detection system for measuring analytes
such as acids, bases, electrolytes, and proteins in solution
phase [21–23]. This electronic taste chip (ETC) system carries
out chemical and immunological reactions on microspheres
positioned in the inverted pyramidal microchamber wells of a
silicon or plastic microchip, which is housed in a miniature
ﬂow cell. Microﬂuidic channels deliver a series of small-
volume reagents and washes to the ﬂow cell, and hence to the
chip and to each one of the microspheres. Optical signals
generated by the reactions on the microspheres are visualized
and captured on a charge-coupled device (CCD) with the use
of transfer optics and a digital video chip. Using the ETC
system, complex immunological assays, such as the ones
developed to quantify cardiac risk factors in serum, can be
performed with small sample volumes, short analysis times,
and markedly reduced reagent costs [22].
Further development of the ETC system has shown that it
could be adapted to the detection of bacteria, spores, and
living cells [24]. We hypothesized that additional modiﬁca-
tions could be made to provide accurate, low-cost CD4 counts
to monitor HIV infection in resource-constrained settings.
We show that a microchip-based system can perform CD4
counts from 16.5 ll of whole blood rapidly, simply, and with a
high degree of accuracy compared to ﬂow cytometry,
particularly for patients with CD4 counts below 500 cells/ll.
We suggest how this prototype system can be readily
developed as a low-cost, portable device for use in
resource-poor settings.
Methods
Flow Cell
The ETC system was originally designed for microsphere-
based assays [21–23]. The modiﬁed version of the ﬂow cell (see
Figure 1) is enclosed within a three-piece metal casing with a
ﬂat platform permanently afﬁxed to a circular vertical
support, which is in turn connected to a screw-on cap.
Within the metal casing there are top and bottom plastic
inserts made from PMMA. Fluids are introduced to and
drained out of the ﬂow cell through integrated stainless steel
tubing within the inserts. The bottom PMMA insert also
features a plastic screen disc that acts as a support for a 3-lm
Nuclepore polycarbonate, track-etch ﬁlter (Whatman, Flor-
ham Park, New Jersey, United States), which serves as a
lymphocyte capture and red blood cell separation membrane.
A gasket between the membrane and the top insert prevents
leaks and ensures that the entire sample is delivered into the
ﬂow cell and ﬁltered through the membrane. The top outlet is
used with lateral ﬂow for the removal of air bubbles.
Fluid Delivery System
In initial studies, we used a single peristaltic pump to
deliver sample and washes to the ﬂow cell. Subsequently, a
partially automated ﬂuid delivery system was developed. This
functional adaptation uses two miniature OEM peristaltic
pumps, each in conjunction with a pinch valve, and 0.031-in.
(0.79-mm) silicone tubing capable of delivering ﬂow rates of
46–920 ll/min to the ﬂow cell. Integrated software (LabVIEW,
National Instruments, Austin, Texas, United States) directs
delivery of whole blood samples and washes to the ﬂow cell
using the appropriate pumps and valves. Sample ﬁltrate,
including red blood cells, is captured in a waste reservoir.
Optical Station and Image Capture
The ﬂow cell was positioned on the stage of a modiﬁed BX2
Olympus (Tokyo, Japan) compound microscope equipped
with a 103objective lens and a high-pressure 100 W mercury
burner arc lamp as a light source. Focusing was maintained
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Visualization of AlexaFluor-647-stained lymphocytes was
achieved using a Cy5 ﬁlter cube (620 nm excitation, 660 nm
long-pass beam splitter dichroic mirror, and 700 nm
emission), while AlexaFluor-488-stained lymphocytes were
visualized with a ﬂuoroisothiocyanate (FITC) ﬁlter cube (480
nm excitation, 505 nm long-pass beam splitter dichroic
mirror, and 535 6 25 nm emission). For each study
participant, images were obtained from each of ﬁve non-
overlapping regions of the lymphocyte capture membrane in
the ﬂow cell, using a 12-bit CCD digital camera (DVC, Austin,
Texas, United States) mounted on the microscope. Each
imaged region represented 0.18 ll of whole blood, so that for
each assay, cells were counted from a total volume of 0.9 llo f
blood. Each region was imaged serially with both ﬁlter cubes.
The corresponding images were stored separately as mono-
chromatic eight-bit images for subsequent digital image
analysis and automated cell counting.
Image Analysis
Images were analyzed using a custom algorithm supported
by Image-Pro Plus (Media Cybernetics, Silver Spring, Mary-
land, United States) processing software. An iterative ap-
proach allowed for ﬂexible analysis of data acquired under
different conditions of illumination, focus, and sampling. For
each iteration, an upper and lower value deﬁned a range of
green or red intensities that were then used to segment the
image. Pixels whose intensity values fell within the deﬁned
range were reassigned values of one, while all others were set
to zero. The process yielded a binary version of the original
eight-bit image. A lymphocyte selection algorithm was then
applied. Objects (i.e., lymphocytes) were deﬁned as contig-
uous groups of pixels with values of one. Object selection was
reﬁned by a lymphocyte proﬁle (deﬁned by size, aspect ratio,
and uniformity); objects not ﬁtting the proﬁle were not
counted. The number of counted objects was recorded for
each iteration. From one iteration to the next, the upper and
lower intensity limits used to segment the image were both
increased by a single intensity count. The ﬁnal cell count per
image was the maximum object count over 256 iterations
(upper intensity limits 1!255) for which the average object
roundness fell below a threshold value. In this manner, the
software algorithm determined the optimal analysis param-
eters for each image individually, greatly relaxing the
stringency of image capture requirements. Cell counts were
recorded in a spreadsheet as numbers of CD4
þCD3
 ,
CD4
þCD3
þ, CD4
 CD3
þ, CD8
þCD3
 , CD8
þCD3
þ, CD8
 CD3
þ,
and CD4
þCD8
þ cells, depending on the combination of
antibodies used. Absolute CD4 counts were recorded as the
summed number of CD4
þCD3
þcells counted over ﬁve images,
normalized per microliter of imaged blood. CD4:CD8 ratios
were recoded as the ratio of CD4
þCD3
þ cells to CD8
þCD3
þ
cells counted over ﬁve images. Relative CD4 abundance as a
percentage of total T lymphocytes was recorded as 100 times
the ratio of CD4
þCD3
þ cells to total CD3
þ cells, with cells
counted over ﬁve images.
Lymphocyte Staining and Delivery
Antibodies utilized in these studies were stored at 4 8C and
centrifuged to remove precipitated material prior to use.
This process ensured removal of ﬂuorescent particulate
matter that could be captured by the membrane and might
interfere with imaging. For the initial dilution control
studies, CD4 cells were puriﬁed by immunomagnetic separa-
tion from donor buffy coats. CD4 cells labeled with
AlexaFluor-488-conjugated anti-CD4 antibodies (A21335,
clone 289–14120, Molecular Probes, Eugene, Oregon, United
States) were introduced to the ﬂow cell in amounts ranging
from zero to 200,000 cells, and washed with phosphate
buffered saline (PBS). For whole blood studies, 33 ll of whole
blood collected by venipuncture was incubated at ambient
temperature (20–25 8C) with 3 ll of AlexaFluor-488- and
AlexaFluor-647-conjugated antibodies to CD4 and CD3
(A21332, clone 289–13801, Molecular Probes), respectively,
and allowed to react for 8 min. Similarly, for CD8
enumeration, 33 ll of whole blood with 3 ll of AlexaFluor-
488- and AlexaFluor-647-conjugated antibodies to CD8
(A21340, clone 289–13804, Molecular Probes) and CD3,
Figure 1. Components of the ETC System
A fluid delivery system is used to introduce sample containing fluorescently stained lymphocytes in whole blood and wash buffer to a capture flow cell.
Lymphocytes captured within the flow cell are visualized with a fluorescence imaging station using a mercury pressure lamp as a light source, and a
CCD for image collection. Raw data images are then processed and analyzed using an automated algorithm run by an attached computer. The flow cell
includes a polymer membrane supported on a chip and two transparent polymethylmethacrylate inserts that allow for the optical evaluation of
captured lymphocytes.
DOI: 10.1371/journal.pmed.0020182.g001
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temperature. Stained blood samples were brought up to 1,000
ll with PBS, half of which was introduced directly into the
ﬂow cell (representing 16.5 ll of the original sample of blood)
and then washed with 1 ml of PBS. Because red blood cells are
mechanically separated from white blood cells, red blood cell
lysis is not necessary. Images of labeled cells captured on the
membrane were obtained and analyzed as described above.
For SEM (scanning electron microscopy), a ﬁxative (2%
paraformaldehyde/2.5% glutaraldehyde) was added into the
ﬂow cell and rinsed with PBS. The ﬁlter was removed from
the ﬂow cell, ﬁxed for 90 s with OsO4 vapor, and then
dehydrated with EtOH/HMDS. The same SEM protocol was
applied to a drop of whole blood on a glass slide.
Study Participants and Comparison to Flow Cytometry
Blood was obtained from HIV-1-uninfected control par-
ticipants and HIV-infected participants at the Massachusetts
General Hospital in Boston, Massachusetts, United States, and
from HIV-infected participants at the Botswana–Harvard
AIDS Institute HIV Reference Laboratory in Gaborone,
Botswana. The Botswana samples originated from a study of
HIV-infected pregnant women attending maternal–child
health clinics in Gaborone or three nearby villages, Molepo-
lole, Mochudi, and Lobatse. Six infants were also included in
the study. Three milliliters of venous whole blood was
collected from each participant (in EDTA anticoagulant).
All samples were run on the microchip on the day of blood
collection. Parallel samples were processed using standard
four-color ﬂow cytometry on a Becton Dickinson FACSCa-
libur, using the MultiTEST reagents and TruCOUNT beads,
and analyzed using MultiSET software. All samples were
processed by ﬂow cytometry according to standard operating
procedure in the HIV reference laboratory in Botswana. The
majority were processed within 24 h of blood collection, and
all were processed and analyzed within 72 h of blood
collection. A total of 70 participants were enrolled, including
64 adults and six infants. Three adults did not have ﬂow
cytometry results available, leaving 67 participants for
analysis. The study was approved by the institutional review
boards of the participating institutions. For a preliminary
assessment of assay variability, blood from a single study
participant was assayed as described above 20 separate times
over the course of a single afternoon by a single operator.
Statistical Methods
The accuracy of the microchip-based CD4 counting system
was determined by comparing results directly to parallel
samples processed by ﬂow cytometry using Passing–Bablok
regression analysis and the Bland–Altman methods compar-
isons approach [25,26]. For assay reproducibility, a coefﬁcient
of variance was calculated from 20 replicates of a single
participant. Data were analyzed and processed using Analyse-
It software (Analyse-It Software, Leeds, United Kingdom).
Results
In initial experiments using the original ETC system [21–
23], microspheres were coated with monoclonal antibodies to
the lymphocyte surface markers CD3, CD4, or CD8, followed
by microﬂuidic delivery of ﬂuorescently labeled lymphocytes
from whole blood obtained from non-HIV-infected partic-
ipants. Although lymphocytes were readily captured, precise
quantiﬁcation of cell numbers and CD4 cell counts were not
possible using the microsphere as a surface for lymphocyte
capture (data not shown). We next modiﬁed the ﬂow cells
with a disposable, microporous membrane ﬁlter for lympho-
cyte capture. A single polycarbonate, track-etch membrane
with 3-lm pores was immobilized and secured within the ﬂow
cell, creating a lymphocyte capture surface with a surface
area of 80 mm
2. Whole blood samples were delivered to the
ﬂow cell from a sample reservoir tube, and the membrane
within the ﬂow cell was washed with PBS from a second
reservoir. As in the original ETC system, cells were imaged
under ﬂuorescence optics using a mercury arc lamp light
source and a CCD camera (Figure 1).
To conﬁrm that cells could be adequately captured, 33 llo f
unprocessed whole blood from non-HIV-infected partici-
pants was incubated for 8 min with ﬂuorophore-conjugated
anti-CD4 antibodies, and delivered by a peristaltic pump to
the modiﬁed microﬂuidics chip. Red blood cells passed
readily through the pores under appropriate ﬂuid ﬂow
conditions. In contrast, the majority of white blood cells
were captured onto a single imaging focal plane (Figure 2).
This mechanical separation of autoﬂuorescent red blood cells
allows for the imaging and counting of white blood cells from
unprocessed whole blood without additional sample process-
ing, such as centrifugation or red blood cell lysis. Using the
digital imaging system originally developed for microsphere-
based capture in the ETC system, ﬂuorescently labeled white
blood cells can then be imaged directly on the chip and
counted.
To assess the analytical validity of the membrane-based
microchip system, we ﬁrst performed a dilution control study
to evaluate the correlation between total ﬂuorescence
intensity and the absolute number of puriﬁed CD4 cells from
non-HIV-infected participants (labeled with ﬂuorophore-
conjugated anti-CD4 antibody) captured in the microcham-
ber. The results show a linear correlation between the
number of cells in the sample and the intensity of light
emitted from the membrane ﬁlter (R
2 ¼ 0.999) for a range of
CD4 cell counts relevant to advanced HIV disease (0–200 CD4
cells/ll blood) (Figure 3). This dose–response study estab-
lished proof of the concept that a modiﬁed microﬂuidic ﬂow
cell and a digital image analysis system can accurately detect
and measure populations of whole blood lymphocytes labeled
with ﬂuorescent markers.
We next quantiﬁed the percentages of CD3, CD4, and CD8
cells in whole blood samples from healthy control partic-
ipants using this system. Prior to delivery to the ﬂow cell, we
labeled a 33-ll whole blood sample with 3 ll of ﬂuorophore-
conjugated anti-CD3 and anti-CD4 antibodies for 8 min off
chip, then diluted the sample with 961 ll of PBS, and
delivered 500 ll of the resulting sample (containing 16.5 llo f
blood) to the ﬂow cell using a ﬂuidics controller. Digital
images from one region of the lymphocyte capture mem-
brane were obtained with two different emission ﬁlters, one
speciﬁc for the AlexaFluor-488-conjugated antibody used to
stain CD4
þ T lymphocytes green (Figure 4A), and the other
speciﬁc for the AlexaFluor-647-conjugated antibody used to
stain CD3
þ T lymphocytes red (Figure 4B). Automated digital
merging of the two images and image processing allowed the
system to distinguish the CD3
þCD4
þ Tl y m p h o c y t e so f
interest (i.e., ‘‘CD4 cells’’), which appear yellow, from the
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þCD3
  monocytes (green) and the CD3
þCD4
  T lympho-
cytes (red) (Figure 4C).
We next developed a custom algorithm for translating
these digital images into accurate CD4 and CD8 T cell counts
using pixel analysis with the aid of a commercial image
processing package. Automated counting of the three subsets
of cells was based on object size, aspect ratio, and uniformity,
iterated across the range of color intensity levels. As shown in
Figure 4D, a binary mask ﬁrst removes the unwanted cell
types, and residual objects representing CD4 T cells are
counted. A similar protocol was applied to a second aliquot of
blood stained with AlexaFluor-647-conjugated CD3-speciﬁc
antibody and AlexaFluor-488-conjugated CD8-speciﬁc anti-
body to visualize and count CD3
þCD8
þ T lymphocytes.
In order to calculate an absolute CD4 count with standard
ﬂow cytometry, one of two measures must be undertaken to
calculate a concentration in cells per microliter. Either a
standardized reference reagent, such as calibration beads at a
known concentration, can be added to the assay (‘‘single-
platform’’ ﬂow cytometry), or an absolute total lymphocyte
count in cells per microliter can be obtained on a hematology
analyzer (‘‘dual-platform’’ ﬂow cytometry). The microchip
assay we describe here uses a direct volumetric method and
functions as a single-platform approach. By delivering a
consistent volume of blood to the ﬂow chamber (16.5 llo f
stained whole blood, diluted to a total volume of 500 llo f
PBS), and calculating the unit volume of blood per digital
image (0.18 ll), we were able to count the total number of
CD4
þCD3
þcells in 0.9 ll of blood, and determine the absolute
CD4 count per microliter.
We next tested this rapid, whole blood microchip assay in a
series of samples acquired in an HIV reference laboratory in
Botswana. Seventy consecutive HIV-infected participants
presenting to the HIV reference laboratory for standard
CD4 counting as part of a vertical transmission study were
enrolled, of whom 64 were adult women and six were infants.
Parallel samples were processed by standard four-color ﬂow
cytometry on a Becton Dickinson FACSCalibur. The time
from blood collection to complete analysis and results
reporting using the chip-based assay was approximately 15
min per sample. Three adult participants did not have valid
Figure 2. The Membrane Flow Cell Selectively Captures Lymphocytes
and Provides for the Removal of Red Blood Cells without Sample
Processing
(A) A whole blood sample collected atop a glass slide and imaged by a
scanning electron microscope reveals the overabundance of red blood
cells in the sample.
(B) A whole blood sample processed through the flow cell reveals that
lymphocytes are captured on the membrane support while red blood
cells are largely excluded from within the cell. Arrows indicate red blood
cells passing through the membrane.
(C) Fluorescent antibody stain specific for a lymphocyte marker is used to
visualize captured lymphocytes within the flow cell in a representative
single-color data image.
DOI: 10.1371/journal.pmed.0020182.g002
Figure 3. CD4 Lymphocyte Dose Response
Purified CD4 cells were labeled with AlexaFluor-488-conjugated anti-CD4
antibodies, introduced to the flow cell in amounts ranging from zero to
200,000 cells and imaged. There is a linear correlation between the
number of cells in the sample and the intensity of light emitted from the
membrane filter (R
2 ¼ 0.999).
DOI: 10.1371/journal.pmed.0020182.g003
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infants for analysis.
Representative processed data images from three partic-
ipants, two adult women and one infant, are shown in Figure
5. Figure 5A shows a 31-y-old woman with an absolute CD4
count by ﬂow cytometry of 83 cells/ll. While numerous CD3
þ
T cells (red) are present as well as scattered monocytes
(green), her low CD4 count is reﬂected in the few double-
Figure 4. Data Collection and Processing for Digital Images Obtained from a Single Diluted Whole Blood Specimen from an HIV-Infected Participant
A total of 16.5 ll of whole blood stained with antibodies specific for CD4 and CD3 markers is delivered to the flow cell after 8 min, and an image of the
same region of the membrane is obtained with two different emission filters.
(A) AlexaFluor-488-conjugated anti-CD4 antibody stains CD4
þ cells (T lymphocytes and monocytes) green.
(B) AlexaFluor-647-conjugated anti-CD3 antibody stains CD3
þ T lymphocytes red.
(C) By digitally merging the two images, CD3
þCD4
þ T lymphocytes (i.e., ‘‘CD4 cells’’) appear yellow and are distinguished from CD4
þCD3
  monocytes
(green) and CD3
þCD4
  T lymphocytes (red).
(D) A lymphocyte selection algorithm is applied to the merged image, based on a lymphocyte profile as defined by size, shape, and uniformity. Objects
not fitting the lymphocyte profile are deleted while remaining objects are selected and ultimately counted. A similar protocol to count CD8 cells is used
in each participant.
Boxed region indicates two CD4
þcells (yellow in [C]) in the original (A and B), merged (C), and processed (D) images. Large green and red objects seen
in some images represent aggregates of fluorescent antibody.
DOI: 10.1371/journal.pmed.0020182.g004
Figure 5. Representative Processed Data Images from Three Participants in Botswana
The participants included (A) a 31-y-old woman with a CD4 count of 83 cells/ll by flow cytometry; (B) a 33-y-old woman with a CD4 count of 271 cells/ll
by flow cytometry; and (C) a 5-mo-old infant with an absolute CD4 count of 2,098 cells/ll and a CD4:CD8 ratio of 1.80 by flow cytometry. In these
images, CD3
þCD8
þ T cells appear red, monocytes appear green, and CD3
þCD4
þ T cells appear yellow. Each image reflects 0.18 ll of whole blood.
DOI: 10.1371/journal.pmed.0020182.g005
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þCD4
þ T cells (yellow) seen in the image. Similar
representative data images from a young woman with a CD4
count of 271 cells/ll by ﬂow cytometry and a 5-mo-old infant
with a CD4 percentage of T lymphocytes of 0.39 by ﬂow
cytometry are also shown in Figure 5B and 5C, respectively.
These images illustrate the dynamic range of the membrane
capture and digital image analysis system, including the
ability to quantify both absolute CD4 counts and CD4
percentages.
We compared results from our microchip assay with results
available from ﬂow cytometry, the latter obtained on a
FACSCalibur through standard clinical laboratory operating
procedures. The data for adult absolute CD4 counts are
plotted in the Bland–Altman methods comparison plot
shown in Figure 6. For 61 adult participants with CD4 counts
ranging from 35 to 1,087 cells/ll (mean, 372 cells/ll) by ﬂow
cytometry, results show a good correlation between absolute
CD4 counts measured by our microchip assay and those
measured by ﬂow cytometry. Bland–Altman methods com-
parison analysis shows a bias of  50 cells/ll (95% conﬁdence
interval,  81 to  20 cells/ll), and good 95% limits of
agreement (Figure 6). Several of the results from participants
at the higher end of absolute CD4 counts fall outside the 95%
limits. For these participants, individual lymphocytes may
overlap in the digital images (as seen in Figure 5C), which can
interfere with the accuracy of the lymphocyte counting
algorithm. In resource-limited settings, the primary use of
CD4 counts is as a trigger to initiate antiretroviral therapy,
which typically occurs at a CD4 count of 200 cells/ll. Higher
CD4 count thresholds of 350 and 500 cells/ll are also used to
increase the intensity of monitoring. For these values, the
sensitivity and speciﬁcity of our method are: CD4 , 250,
sensitivity ¼ 0.86, speciﬁcity ¼ 0.81; CD4 , 350, sensitivity ¼
0.97, speciﬁcity ¼ 0.83; and CD4 , 500, sensitivity ¼ 0.96,
speciﬁcity ¼ 0.85.
One important application of our method is in pediatric
HIV monitoring. The wide range of normal absolute CD4
counts in infants and children requires the use of CD4:CD8
ratios or CD4 percentages in pediatric infection. Results for
CD4:CD8 ratios and CD4 percentages of T lymphocytes for all
67 participants (61 adults and six infants) are shown in Fig-
ure 7. Agreement, bias, and correlations between the micro-
chip method and ﬂow cytometry are excellent for both CD4
percentages of T lymphocytes (Figure 7A and 7B) and
CD4:CD8 ratios (Figure 7C and 7D). Bland–Altman plots for
both CD4 percentages of T lymphocytes and CD4:CD8 ratios
show low proportional bias, with tight 95% limits of agree-
ment. Correlations are excellent for both CD4 percentages of
T lymphocytes (r ¼ 0.98, p , 0.0001) and CD4:CD8 ratios (r ¼
0.98, p , 0.0001). Overall, the data show that all three
approaches to measuring CD4 cell counts can be accurately
quantiﬁed using the microchip method, and that both adult
and pediatric CD4 results can be obtained.
To determine assay variability, we examined 20 replicate
samples of blood from a single participant over the course of
one day, using the established basic protocol. We determined
that the coefﬁcient of variance was 12% (data not shown),
which is similar to other methods of CD4 counting [27].
Although the assay described here introduced 16.5 ll of blood
into the system, the actual volume of blood analyzed by digital
image analysis is only 0.90 ll. We have conducted preliminary
studies that suggest that we can accurately measure CD4
counts from less than 5 ll of blood obtained via ﬁngerstick
(data not shown); additional studies will be required to assess
the correlation between CD4 counts obtained by ﬁngerstick
and by venipuncture.
Figure 6. Methods Comparison and Correlation Studies for Absolute CD4
Counts in 61 Adults in Botswana
Bland–Altman methods comparison plot comparing absolute CD4 cells
per microliter of whole blood obtained by the microchip system as
compared to standard four-color flow cytometry processed in parallel on
a FACSCalibur in 61 HIV-infected adult participants. There is a propor-
tional bias of  50 cells/ll relative to flow cytometry. Grey line indicates
zero bias. Red lines indicate upper and lower 95% limits of agreement.
DOI: 10.1371/journal.pmed.0020182.g006
Figure 7. Methods Comparison and Correlation Studies for CD4
Percentages of Total T Cells and CD4:CD8 Ratios in 67 Human Subjects
(A and B) CD4 percentages of total T cells and (C and D) CD4:CD8 ratios
in 67 human participants, including 61 adults and six children. In
Passing–Bablok correlation plots (A and C), solid black lines indicate
identity, blue lines indicate the observed correlations, and dashed black
lines indicate 95% confidence limits. Correlations for CD4 percentages of
total T cells (r ¼ 0.98, p , 0.0001) and CD4:CD8 ratios (r ¼ 0.98, p ,
0.0001) are shown. For Bland–Altman methods comparison plots (B and
D), notations are as described in Figure 6 caption.
DOI: 10.1371/journal.pmed.0020182.g007
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Our results provide proof of principle that low-cost
microﬂuidic structures combined with ﬂuorescence imaging
and digital image analysis can be successfully applied to the
measurement of CD4 cell counts, which are critical to the
clinical management of HIV infection. The method described
here can deliver both absolute CD4 counts for adult
monitoring, and CD4 percentages or CD4:CD8 ratios for
pediatric monitoring. Most importantly, the rapid and
accurate CD4 assessments obtained with this method,
together with its anticipated low cost relative to ﬂow
cytometry, may make this type of approach ideal for
resource-scarce settings. As our results show, this method
may be less accurate at the higher range of CD4 counts, where
cells may be more likely to overlap in our digital images.
While this may limit its applicability, our method is accurate
at CD4 counts below 500 cells/ll, which represent the
clinically relevant CD4 levels in resource-poor settings. In
addition, both the bias in the method described here ( 50
cells) and the accuracy at higher CD4 counts are likely to be
improved signiﬁcantly by the further development of a
disposable microﬂuidic cartridge, where the volume of
distribution of the sample will be much smaller, and more
accurate volumetric control will be possible.
Our study was designed to evaluate the accuracy of our
method against the gold standard in a population of adults.
During enrollment, a small number of pediatric samples were
made available to us by the staff at Princess Marina Hospital
in Botswana. We chose to include these samples in the data
presented here to provide proof of principle that pediatric
CD4 percentages can also be assessed with this method.
Although only six pediatric samples were available, limiting
claims of statistical signiﬁcance, we believe the issue of
pediatric CD4 count monitoring to be of such importance
that the data merited inclusion. Excluding the six pediatric
samples does not affect the analysis.
The results presented here were obtained with a stationary,
tabletop monitoring system using a standard epiﬂuorescence
microscope and commercial image processing software.
While the methods we described provide the basis for a
highly portable and ﬂexible miniaturized CD4 counting
system, it should be emphasized that a number of additional
developments are required to enable the widespread use of
this approach in resource-limited settings. With additional
engineering of optics, electronics, and mechanical compo-
nents along with advancements in integrated microﬂuidic
systems, it should be possible to develop a point-of-care
instrument that is battery-powered, uses simple light emitting
diodes (LEDs), and secures analyzable digital images with
affordable video imaging chips. When combined with an
embedded microprocessor and disposable assay cartridges for
both adult and pediatric monitoring manufactured from
injection-molded plastic, it should be possible to create a
functional CD4 counting device that can be used at the point
of care. Further trials in a larger, more diverse cohort of
patients, including adult men and children, will be necessary
to conﬁrm the accuracy of the method, including an assess-
ment of assay bias and reproducibility. Such a device is
currently in commercial development, and may be available
by early 2006. While it is too early to provide an accurate cost
estimate for a portable instrument and disposable plastic CD4
assay, we expect the equipment cost would be substantially
Table 1. A Comparison of Methods for CD4 Determination
Method Manufacturer/
Model
Equipment Assay Time to Result
(Minutes)
Adult or
Pediatric
Estimated Cost
(USD$)
a
Location
of Use
Estimated
Cost
(USD$)
a
Sample
Volume
Sample
Preparation
Flow cytometry Beckman Coulter $75,000–125,000 Central reference
laboratory
$5–50 100 ll .3 pipet steps 20–30 Both
EPICS XL
Becton Dickinson
FACSCalibur
Single-purpose
flow cytometry
Becton Dickinson
FACSCount
$20,000–50,000 District/regional
facility
$5–25 50 ll 2 pipet steps 15 Adult only
Guava Easy CD4 $5–10 10 ll 3 pipet steps 30 Adult only
Partec CyFlow
b $3–10 50 ll 3 pipet steps 15 Both
PointCare FlowCare
c $10 5 ml None 30 Both
Microbead separation Coulter Cytospheres $2,000 District/regional
facility
; $4–7 ;100 ll  3 pipet steps,
manual count
30–45 Adult only
Dynal Dynabeads
Microchip digital imaging In development ,$5,000 Point of care In development
d ,10 ll None
d ;10 Both
Compared with flow cytometric and related methods, including newer systems, the described method can be adapted to a portable device offering true point-of-care testing, although likely at lower throughput than current methods.
Compared with microbead-based microscopic methods, the described method is significantly less labor intensive and higher throughput.
aCosts are rough estimates for resource-limited countries. CD4 equipment and assay costs vary significantly by country, and a variety of discounts are available based on volume purchasing, and equipment purchase versus equipment lease
options. Assay costs are intended to reflect cost per patient result for reagents, consumables, sample collection, processing, and overhead, including personnel costs, but are not intended to reflect amortization of equipment purchase or
equipment maintenance fees, which can be as high as $15,000 per year.
bPartec CyFlow is available in a mobile version powered by a 12-V automobile battery.
cPointCare’s technology uses nonfluorescent detection of side angle light scatter information from a flowing sample, and thus differs slightly from traditional flow cytometry.
dMicrofluidic cartridges with embedded reagents are now in development. These systems are projected to use significantly less reagents than flow cytometry, and final assay costs are likely to be low. For the prototype described here, two
pipet steps were required. These steps will be integrated components of the microfluidic cartridges, which will require no sample preparation.
DOI: 10.1371/journal.pmed.0020182.t001
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similar to assays using existing methods (Table 1).
Although several CD4 counting systems are now used in
resource-limited settings, they remain suboptimal to meet the
needs of HIV care and treatment scale-up. None can truly be
used at the point of care beyond a district hospital or similar
facility, and either the capital and operating costs remain
high, or throughput is low, or both (Table 1). Pediatric
monitoring using CD4 percentages also remains largely
unavailable. The method we describe here addresses several
of the limitations of performing diagnostic assays in resource-
limited settings. First, sample volumes are minimal, so that
tests can be performed on ﬁngerstick samples of blood,
circumventing the need for venipuncture, and minimizing
both medical waste and operator exposure to biohazardous
material. Second, reagent use is minimized in the microchip
system, reducing reagent costs by as much as 90%. Third,
labor- and equipment-intensive sample preparation is elim-
inated. Fourth, the microchip CD4 assay is extremely rapid.
CD4 results in the prototype system described here are
available in less than 15 min from the time of blood
collection. In a mature microﬂuidic device with push-button
operation, results should be available in less than 10 min, and
thus can be used to make real-time clinical decisions at the
point of care. Fifth, the assay is technically simple, analogous
to a portable glucometer, and ultimately will be useable by a
health-care worker in remote settings with minimal training,
extending the reach of CD4 assays to district hospitals and
remote clinics, and reducing labor costs. Sixth, both adult and
pediatric monitoring are possible.
We believe that the future of low-cost diagnostics for use in
the developing world lies in the development of new lab-on-a-
chip technologies that integrate sample preparation and
sample measurement systems into miniaturized devices with
minimal power requirements. Preliminary cost estimates for
the instrumentation here described suggest, at a minimum, a
10-fold reduction in the cost for the associated measurement
system. Further, reagent consumption for the microchip
system can be reduced by a similar factor relative to ﬂow
cytometry, while sample storage and shipping costs are
expected to be reduced dramatically by virtue of the point-
of-care capabilities of this new lab-on-a-chip structure. The
importance of microtechnologies to the realities of labora-
tory infrastructure worldwide has been recognized previously
[28–30]. Although CD4 counting represents the most urgent
need in HIV diagnostics for resource-poor settings, the
microchip platform is adaptable to other important assays.
Through the interface of the lymphocyte capture membrane
described here with the previously reported microchip
arrays, cellular assays like CD4 counts can be multiplexed
with other molecular biomarker measurements (i.e., proteins
and nucleic acids) on a single miniaturized chip. The rapid
extension of the chip-based CD4 counting method described
here to HIV RNA measurements, diagnostics for opportun-
istic infections, liver enzymes, and other biochemical markers
of interest in infectious disease is feasible.
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Patient Summary
Background Most HIV-infected people don’t develop AIDS right away,
because their immune systems can keep the virus in check for months
and sometimes years. In general, doctors don’t recommend that infected
people start taking HIV medications while their immune system is still
healthy. Doctors know whether or not a patient’s immune system is
healthy-and therefore whether or not to start treatment-by measuring
the "CD4 count." This is the number of CD4 cells in a sample of blood.
CD4 cells, also called CD4+ T cells, are a type of white blood cell that
fights infection. HIV destroys CD4 cells, weakening the body’s immune
system and ultimately causing AIDS. CD4 counts should be determined
before a patient receives antiretroviral therapy and then measured
regularly while the patient is on therapy.
Why Was This Study Done? Most tools available to count CD4 cells are
large and expensive to buy, and every actual count is also expensive and
difficult to carry out. These tools are therefore unsuitable for many low-
income countries. The researchers wanted to develop a tool that allows
easier and cheaper measurement of CD4 cells, and is small and simple
enough that health-care workers can take it to patients when they visit
them in remote areas.
What Did the Researchers Do? They built a prototype for a new tool
that counts CD4 cells in a simpler and cheaper way. They then took
samples from 61 adults and six children and compared the results when
they used both the standard technologies and their prototype counter.
What Did They Find? They found that their prototype works well and is
indeed cheaper and easier to use. It also appears to be just as reliable as
the large and more complicated machines in helping doctors make
decisions about when to start therapy and when to change therapies.
They have done enough samples from adults infected with HIV to be
confident about that. It looks like it might work for infected children as
well, but they haven’t done enough child samples yet to be certain.
What Does This Mean? This suggests that with some additional work, it
should be possible to develop a handheld CD4 counter that is cheap,
easy, and transportable. This could make a big difference for the care of
HIV patients in developing countries and other remote areas.
What Next? There is still more development work to do to get from the
prototype to a handheld counter, and the researchers should also study
more samples from children to see whether the new test is equally
reliable for pediatric patients.
Additional Online Resources Information about CD4 monitoring for
HIV/AIDS patients can be found at the following Web sites.
World Health Organization (search for CD4 count):
http://www.who.int/en/
The World Health Organization’s specific review of CD4 counting
technologies:
http://www.who.int/3by5/amds/Suzanne_Crowe.pdf
The Well Project:
http://www.thewellproject.org/
The Well Project’s specific page on CD4 counts:
http://www.thewellproject.org/Treatment_and_Trials/First_Things_First/
Understanding_CD4_and_CD8_Cells.jsp
Find Diagnostics, an organization focused on affordable diagnostics for
infectious diseases worldwide:
http://www.finddiagnostics.org/
The Forum for Collaborative HIV Research, a consortium with an
advocacy and funding role for HIV/AIDS research priorities, including
low-cost CD4 and viral load tests:
http://www.hivforum.org/
Project Inform (search for CD4 and monitoring):
http://www.projectinform.org/
and Melinda Gates Foundation, and the Doris Duke Charitable
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collection and analysis, decision to publish, or preparation of the
manuscript.
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